The roles of galactitol, galactose-1-phosphate, and phosphoglucomutase in galactose-lnduced toxicity in Saccharomyces cerevisiae

Biotechnology and Bioengineering

Volumn 101, Issue 2, 2008, Pages 317-326

  De Jongh, Willem A ^a   Bro, Christoffer ^a   Ostergaard, Simon ^a   Regenberg, Birgitte ^a   Olsson, Lisbeth ^a   Nielsen, Jens ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Galactitol; Galactose toxicity; Galactose 1 phosphate; Galactosemia; Intracellular metabolites; Phosphoglucomutase

Indexed keywords

BIOCHEMICAL ENGINEERING; CONCENTRATION (PROCESS); ENZYME ACTIVITY; GENES; GLUCOSE; STRAIN; YEAST;

GALACTITOL; GALACTOSE TOXICITY; GALACTOSE-1-PHOSPHATE; GALACTOSEMIA; INTRACELLULAR METABOLITES; PHOSPHOGLUCOMUTASE;

TOXICITY;

GALACTITOL; GALACTOSE; GALACTOSE 1 PHOSPHATE; GALACTOSE PHOSPHATE; PHOSPHOGLUCOMUTASE; UNCLASSIFIED DRUG; GAL1 PROTEIN, S CEREVISIAE; GAL10 PROTEIN, S CEREVISIAE; GALACTOKINASE; GALACTOSE-1-PHOSPHATE; MULTIENZYME COMPLEX; SACCHAROMYCES CEREVISIAE PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; ENZYME INHIBITION; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; GAL1 GENE; GAL10 GENE; GAL2 GENE; GAL7 GENE; GENE OVEREXPRESSION; GROWTH RATE; NONHUMAN; SACCHAROMYCES CEREVISIAE; TOXICITY; CULTURE MEDIUM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PLASMID;

SACCHAROMYCES CEREVISIAE;

CULTURE MEDIA; GALACTITOL; GALACTOKINASE; GALACTOSE; GALACTOSEPHOSPHATES; MULTIENZYME COMPLEXES; PHOSPHOGLUCOMUTASE; PLASMIDS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TRANS-ACTIVATORS;

EID: 51649124324     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21890     Document Type: Article

References (52)

1. Aiello DP, Fu L, Miseta A, Bedwell DM. 2002. Intracellular glucose 1-phosphate and glucose 6-phosphate levels modulate Ca2+ homeostasis in Saccharomyces cerevisiae. J Biol Chem 277:45751-45758.
2. Alani E, Cao L, Kleckner N. 1987. A method for gene disruption that allows repeated use of URA3 selection in the construction of multiply disrupted yeast strains. Genetics 116:541-545.
3. Backburn EH, Greider CW, Szostak JW. 2006. Telomeres and telomerase: The path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 10:1133-1138.
4. Boeke JD, LaCroute F, Fink GR. 1984. A positive selection for mutants lacking orotidine-5′-phosphate decarboxylase activity in yeast: 5-Fluoro-orotic acid resistance. Mol Gen Genet 197:345-346.
5. Bro C, Knudsen S, Regenberg B, Olsson L, Nielsen J. 2005. Improvement of galactose uptake in Saccharomyces cerevisiae through overexpression of phosphoglucomutase: Example of transcript analysis as a tool in inverse metabolic engineering. Appl Environ Microbiol 71:6465-6472.
6. Carrai PM, Dougherty B, Ross-Macdonald P, Browman K, FitzGerald K. 2003. Model systems in drug discovery: Chemical genetics meets genomics. Pharmacol Ther 2:183-220.
7. Christacos NC, Marson MJ, Wells L, Riehman K, Fridovich-Keil JL. 2000. Subcellular localization of galactose-1-phosphate uridylyltransferase in the yeast Saccharomyces cerevisiae. Mol Genet Metab 70:272-280.
8. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P. 1992. Multifunctional yeast high-copy-number shuttle vectors. Gene 110:119-122.
9. Ficicioglu C, Yager C, Segal S. 2005. Galactitol and galactonate in red blood cells of children with the Duarte/galactosemia genotype. Mol Genet Metab 84:152-159.
10. Flynn JM, Cammarata PR. 2006. Estradiol attenuates mitochondrial depolarization in polyol-stressed lens epithelial cells. Mol Vis 12:271-282.
11. Fu L, Miseta A, Hunton D, Marchase RB, Bedwell DM. 2000. Loss of the major isoform of phosphoglucomutase results in altered calcium homeostasis in Saccharomyces cerevisiae. J Bio Chem 275:5431-5440.
12. Gietz D, St. Jean A, Woods RA, Schiestl RH. 1992. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res 20:1425.
13. Gitzelmann R. 1995. Galactose-1-phosphate in the pathophysiology of galactosemia. Eur J Pediatr 154:245-2449.
14. Gonzalez B, Francois J, Renaud M. 1997. A rapid and reliable method for metabolite extraction in yeast using boiling buffered ethanol. Yeast 13:1347-1355.
15. Hunter M, Heyer E, Austerlitz F, Angelicheva D, Nedkova V, Briones P, Gata A, de Pablo R, Laszlo A, Bosshard N, Gitzelmann R, Tordai A, Kalmar L, Szalai C, Balogh I, Lupu C, Corches A, Popa G, Perez-Lezaun A, Kalaydjieva LV. 2002. The P28T mutation in the GALK1 gene accounts for galactokinase deficiency in Roma (Gypsy) patients across Europe. Pediatr Res 51:602-606.
16. Johnston M, Carlson M. 1992. In: Jones EW, Pringle JR, Broach JR, editors. The molecular and cellular biology of the yeast Saccharomyces: Gene expression. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, p 193-281.
17. Klein CJL, Olsson L, Nielsen J. 1998. Glucose control in Saccharomyces cerevisiae: The role of MIG1 in metabolic functions. Microbiology 144:13-24.
18. Lai K, Elsas LJ. 2000. Overexpression of human UDP-glucose pyrophosphorylase rescues galactose-1-phosphate uridyltransferase-deficient yeast. Biochim Biophys Acta 271:392-400.
19. Lee AY, Chung SK, Chung SS. 1995. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 92:2780-2784.
20. Liang H, Gaber RF. 1996. A novel signal transduction pathway in Saccharomyces cerevisiae defined by Snf3-regulated expression of HXT6. Mol Biol Cell 7:1953-1966.
21. Marinou K, Tsakiris S, Tsopanakis C, Schulpis KH, Behrakis P. 2005a. Suckling rat brain regional distribution of Na+,K+-atpase activity in the in vitro galactosaemia: The effect of 1-cysteine and glutathione. Metab Brain Dis 20:45-54.
22. Marinou K, Tsakiris S, Tsopanakis C, Schulpis KH, Behrakis P. 2005b. Mg2+-ATPase activity in suckling rat brain regions in galactosaemia in vitro. L-Cysteine and glutathione effects. Toxicol in vitro 19:167-172.
23. Mehta DV, Kabir A, Bhat PJ. 1999. Expression of human inositol monophosphatase suppresses galactose toxicity in Saccharomyces cerevisiae: Possible implications in galactosemia. Biochim Biophys Acta 1454:217-226.
24. Melcher K. 1997. Galactose metabolism in Saccharomyces cerevisiae: A paradigm for eukaryotic gene regulation. In: Zimmermann FK, Enzian KD, editors. Yeast sugar metabolism. Lancaster, PA: Technomic Publishing Inc. p 235-269.
25. Murata M, Ohta N, Fujisawa S, Tsai JY, Sato S, Akagi Y, Takahashi Y, Neuenschwander H, Kador PF. 2002. Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation J Diab Complications 16:363-370.
26. Najjar VA, Pullmann , ME. 1954. The occurrence of a group transfer involving enzyme (phophoglucomutase) and substrate. Science 119:631-634.
27. Ning C, Reynolds R, Chen J, Yager C, Berry GT, Leslie N, Segal S. 2001. Galactose metabolism in mice with galactose-1-phosphate uridyltransferase deficiency: Sucklings and 7-week-old animals fed a high-galactose diet. Mol Genet Metab 72:306-315.
28. Ohta Y, Yamasaki T, Niwa T, Goto H, Majima Y, Ishiguro I. 1999. Cataract development in 12-month-old rats fed a 25% galactose diet and its relation to osmotic stress and oxidative damage. Ophthalmic Res 31:321-331.
29. Ostergaard S. 2000. PhD thesis, Technical University of Denmark.
30. Ostergaard S, Roca C, Rønnow B, Nielsen J, Olsson L. 2000a. Physiological studies in aerobic batch cultivations of Saccharomyces cerevisiae strains harboring the MEL1 gene. Biotechnol Bioeng 68:252-259.
31. Ostergaard S, Olsson L, Johnston M, Nielsen J. 2000b. Increasing galactose consumption by Saccharomyces cerevisiae through metabolic engineering of the GAL gene regulatory network. Nat Biotechnol 12:1283-1286.
32. Outeiro TF, Giorgini F. 2006. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol J 3:258-269.
33. Outeiro TF, Muchowski PJ. 2004. Molecular genetics approaches in yeast to study amyloid diseases. J Mol Neurosci 23:49-60.
34. Pail M, Peterbauer T, Seiboth B, Hametner C, Druzhinina I, Kubicek CP. 2004. The metabolic role and evolution of L-arabinitol 4-dehydrogenase of Hypocrea jecorina. Eur J Biochem 271:1864-1872.
35. Palmieri M, Mazur A, Berry GT, Ning C, Wehrli S, Yager C, Reynolds R, Sigh R, Muralidharan K, Langley S, Elsas L II, Segal S. 1999. Urine and plasma galactitol in patients with galactose-1-phosphate uridyltransferase deficiency galactosemia. Metabolism 48:1294-1302.
36. Petrash JM, Murthy BS, Young M, Morris K, Rikimaru L, Griest TA, Harter T. 2001. Functional genomic studies of aldo-keto reductases. Chem Biol Interact 30:673-683.
37. Posternak T, Rosselet JP. 1954. Action de la phosphoglucomutase du muscle sur des acides aldose-1-phosphoriques. Transformation de l'acide galactose-1 -phosphorique. Helv Chim Acta 37:246-250.
38. Riehman K, Crews C, Fridovich-Keil JL. 2001. Relationship between genotype, activity, and galactose sensitivity in yeast expressing patient alleles of human galactose-1-phosphate uridylyltransferase. J Bio Chem 276:10634-10640.
39. Rose MD, Winston F, Hieter P. 1990. Methods in yeast genetics: A laboratory course manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
40. Ross KL, Davis CN, Fridovich-Keil JL. 2004. Differential roles of the Leloir pathway enzymes and metabolites in defining galactose sensitivity in yeast. Mol Genet Metab 83:103-116.
41. Sambrook J, Fritsch EF, Maniatis TM. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
42. Sidbury JB. 1960. In: Gardner LI, editor. Molecular genetics of human disease. USA: Charles C Thomas Publishers, p 61.
43. Smits HP, Cohen A, Buttler T, Nielsen J, Olsson L. 1998. Cleanup and analysis of sugar phosphates in biological extracts by using solid-phase extraction and anion-exchange chromatography with pulsed ampero-metric detection. Anal Biochem 261:36-42.
44. St John TP, Scherer S, McDonell MW, Davis RW. 1981. Deletion analysis of the Saccharomyces GAL gene cluster. Transcription from three promoters. J Mol Biol 152:317-334.
45. Tsakiris S, Marinou K, Schulpis KH. 2002a. The effect of galactose metabolic disorders on rat brain Na+, K+-ATPase activity. Z Naturforsch [C] 57:939-943.
46. Tsakiris S, Marinou K, Schulpis KH. 2002b. The in vitro effects of galactose and its derivatives on rat brain Mg2+-ATPase activity. Pharmacol Toxicol 91:254-257.
47. van Dijken JP, Bauer JP, Brambilla L, Duboc P, Francois JM, Gancedo C, Giuseppin CM, Heijnen JJ, Hoare M, Lange HC, Madden EA, Niederberger P, Nielsen J, Parrou JL, Petit T, Porro D, Reuss M, van Riel N, Rizzi M, Steensma HY, Verrips CT, Vindelov J, Pronk JT. 2000. An interlaboratory comparison of physiological and genetic properties of four Saccharomyces cerevisiae strains. Enzyme Microb Technol 26:706-714.
48. Waggoner DD, Buist NRM, Donnel GN. 1990. Long-term prognosis in galactosaemia: Results of a survey of 350 cases. J Inherit Metb Dis 13:802-818.
49. Wehrli SL, Reynolds R, Chen J, Yager C, Segal S. 2002. Metabolism of 13C galactose by lymphoblasts from patients with galactosemia determined by NMR spectroscopy. Mol Genet Metab 77:296-303.
50. Westergaard SL, Oliveira AP, Bro C, Olsson L, Nielsen J. 2007. A systems biology approach to study glucose repression in the yeast Saccharomyces cerevisiae. Biotechnol Bioeng 96:134-145.
51. Yager CT, Chen J, Reynolds R, Segal S. 2003. Galactitol and galactonate in red blood cells of galactosemic patients. Mol Genet Metab 80:283-289.
52. Yang L, Su Y, Liu W, Jin X, Wu J. 2002. Sugar interaction with metal ions. The coordination behavior of neutral galactitol to Ca(II) and lanthanide ions. Carbohydr Res 337:1485-1493.